A. E. Evsikov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
A. E. Evsikov has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Leonid V. Maslovskii
Central State Medical Academy of Department for Presidential Affairs of the Russian Federation
3 shared publications - Oleg N. Minushkin
Central State Medical Academy of Department for Presidential Affairs of the Russian Federation
3 shared publications - Igor V. Zverkov
Central State Medical Academy of the Administrative Department of the President of the Russian Federation
2 shared publications - A. A. Frolova
Central State Medical Academy of Department for Presidential Affairs of the Russian Federation
1 shared publication D. B. Nikityuk
Federal Research Center for Nutrition, Biotechnology and Food Safety
1 shared publication- I. Yu. Vornacheva
City Clinical Hospital no. 4
1 shared publication
Latest Publications
- Open Access
- 24 October 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 53-63
Comparative efficacy of multi-enzyme products in patients with exocrine pancreatic insufficiency
Introduction. Chronic relapsing pancreatitis or pancreatic resection eventually results in exocrine pancreatic insufficiency, leading to impaired digestion, and metabolic and electrolyte disturbances. Patients with such disorders develop a severe symptom complex associated with increased mortality, which requires early diagnosis and appropriate treatment. Aim. To compare the efficacy and safety of Digestium Forte (pancreatin + hemicellulase) supplement and Ermital in patients with exocrine pancreatic insufficiency based on clinical, instrumental, and laboratory parameters. Materials and methods . We conducted a comparative study using Ermital as a comparator. A total of 101 patients with chronic pancreatitis and exocrine pancreatic insufficiency confirmed by the elastase test results were included in the study. The first group (treatment group) consisted of 52 patients treated with Digestium Forte (pancreatin + hemicellulase) supplement. The second group (comparator group) consisted of 49 patients treated with Ermital. Therapy efficacy was assessed based on clinical data (changes in symptoms and patients’ quality of life using the GSRS questionnaire) and laboratory/instrumental findings (changes in coprogram results, severity of malnutrition, bowel transit time using the carbolene test, and ultrasound examination). Results. The study revealed that adding hemicellulase to pancreatin resulted in a significant reduction in bloating, feeling of fullness, and borborygmi, as well as improved quality of life in patients with exocrine pancreatic insufficiency, starting from week 2 or 3 of treatment. Both products demonstrated comparable efficacy in terms of impact on nutritional status, coprogram parameters, pancreatic transabdominal ultrasound findings, and intestinal transit time (the carbolene test results). Conclusions. The findings derived from study data gave reasons to consider treatment with Digestium Forte (pancreatin + hemicellulase) supplement as a priority approach for patients with exocrine pancreatic insufficiency.
- 24 October 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 53-63
Open AccessComparative efficacy of multi-enzyme products in patients with exocrine pancreatic insufficiency
Introduction. Chronic relapsing pancreatitis or pancreatic resection eventually results in exocrine pancreatic insufficiency, leading to impaired digestion, and metabolic and electrolyte disturbances. Patients with such disorders develop a severe symptom complex associated with increased mortality, which requires early diagnosis and appropriate treatment. Aim. To compare the efficacy and safety of Digestium Forte (pancreatin + hemicellulase) supplement and Ermital in patients with exocrine pancreatic insufficiency based on clinical, instrumental, and laboratory parameters. Materials and methods . We conducted a comparative study using Ermital as a comparator. A total of 101 patients with chronic pancreatitis and exocrine pancreatic insufficiency confirmed by the elastase test results were included in the study. The first group (treatment group) consisted of 52 patients treated with Digestium Forte (pancreatin + hemicellulase) supplement. The second group (comparator group) consisted of 49 patients treated with Ermital. Therapy efficacy was assessed based on clinical data (changes in symptoms and patients’ quality of life using the GSRS questionnaire) and laboratory/instrumental findings (changes in coprogram results, severity of malnutrition, bowel transit time using the carbolene test, and ultrasound examination). Results. The study revealed that adding hemicellulase to pancreatin resulted in a significant reduction in bloating, feeling of fullness, and borborygmi, as well as improved quality of life in patients with exocrine pancreatic insufficiency, starting from week 2 or 3 of treatment. Both products demonstrated comparable efficacy in terms of impact on nutritional status, coprogram parameters, pancreatic transabdominal ultrasound findings, and intestinal transit time (the carbolene test results). Conclusions. The findings derived from study data gave reasons to consider treatment with Digestium Forte (pancreatin + hemicellulase) supplement as a priority approach for patients with exocrine pancreatic insufficiency.
- 27 January 2026
- Published by Alfmed LLC in Medical alphabet
- Vol. 1 (34)
The interrelationship between the exocrine and endocrine functions of the pancreas in health and disease
This article examines the theoretical aspects of the interaction between the exocrine and endocrine parts of the pancreas (P), as well as various pathologies illustrating these processes. The diseases covered include chronic pancreatitis (CP), acute pancreatitis (AP), diabetes mellitus (DM), pancreatic steatosis, and several others. Data on the prevalence of DM in various pancreatic pathologies and the incidence of exocrine pancreatic insufficiency (EPI) in DM are provided. Risk factors for DM in pancreatic pathology are presented. The mechanisms of pathogenesis of these conditions are discussed, and the presented concepts are supported by experimental data. Additionally, several potential therapeutic interventions that may improve treatment efficacy in these conditions are discussed.
- 27 January 2026
- Published by Alfmed LLC in Medical alphabet
- Vol. 1 (34)
The interrelationship between the exocrine and endocrine functions of the pancreas in health and disease
This article examines the theoretical aspects of the interaction between the exocrine and endocrine parts of the pancreas (P), as well as various pathologies illustrating these processes. The diseases covered include chronic pancreatitis (CP), acute pancreatitis (AP), diabetes mellitus (DM), pancreatic steatosis, and several others. Data on the prevalence of DM in various pancreatic pathologies and the incidence of exocrine pancreatic insufficiency (EPI) in DM are provided. Risk factors for DM in pancreatic pathology are presented. The mechanisms of pathogenesis of these conditions are discussed, and the presented concepts are supported by experimental data. Additionally, several potential therapeutic interventions that may improve treatment efficacy in these conditions are discussed.
- Open Access
- 20 January 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 177-185
The effectiveness of the introduction of dietary therapeutic foods in the eradication of Helicobacter pylori in patients with chronic gastritis
Introduction. In recent years, a high resistance of H. pylori infection to antibiotics has been recorded both worldwide and in the Russian Federation. This was the basis for introducing diets that increase the sensitivity of H. pylori to antibiotics into eradication schemes.Aim. To evaluate the effect of specialized therapeutic nutrition products LEOVIT GASTRO on the eradication of H. pylori.Materials and methods. Two study groups were formed: the main group – 22 patients and the control group – 20 patients. The groups were randomized from 42 patients suffering from chronic gastritis associated with H. pylori, by random sampling. To assess the tolerability of treatment, in particular, biochemical blood tests were studied.Results. Therapeutic nutrition provides a significant eradication effect against the background of antibiotic therapy. In 92% of patients, a complete absence of H. pylori contamination was detected, and in 8% of patients the degree of contamination was very weak, although initially it was pronounced, while in the control group, a complete absence of H. pylori contamination was detected in 80% of patients. Analysis of the use of specialized food products indicates the possibility of their use in diseases of the gastrointestinal tract associated with H. pylori, as they promote epithelization, healing of the mucosa, reduction and elimination of inflammation, pain, and discomfort in the gastrointestinal tract.Conclusion. Therapeutic dietary nutrition LEOVIT GASTRO is one of the important factors positively influencing the success rate of eradication treatment.
- 20 January 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 177-185
Open AccessThe effectiveness of the introduction of dietary therapeutic foods in the eradication of Helicobacter pylori in patients with chronic gastritis
Introduction. In recent years, a high resistance of H. pylori infection to antibiotics has been recorded both worldwide and in the Russian Federation. This was the basis for introducing diets that increase the sensitivity of H. pylori to antibiotics into eradication schemes.Aim. To evaluate the effect of specialized therapeutic nutrition products LEOVIT GASTRO on the eradication of H. pylori.Materials and methods. Two study groups were formed: the main group – 22 patients and the control group – 20 patients. The groups were randomized from 42 patients suffering from chronic gastritis associated with H. pylori, by random sampling. To assess the tolerability of treatment, in particular, biochemical blood tests were studied.Results. Therapeutic nutrition provides a significant eradication effect against the background of antibiotic therapy. In 92% of patients, a complete absence of H. pylori contamination was detected, and in 8% of patients the degree of contamination was very weak, although initially it was pronounced, while in the control group, a complete absence of H. pylori contamination was detected in 80% of patients. Analysis of the use of specialized food products indicates the possibility of their use in diseases of the gastrointestinal tract associated with H. pylori, as they promote epithelization, healing of the mucosa, reduction and elimination of inflammation, pain, and discomfort in the gastrointestinal tract.Conclusion. Therapeutic dietary nutrition LEOVIT GASTRO is one of the important factors positively influencing the success rate of eradication treatment.